A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Fulvestrant; Fulvestrant
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms VERONICA
- Sponsors Roche
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 15 Mar 2019 Planned End Date changed from 30 Oct 2022 to 3 Mar 2022.
- 15 Mar 2019 Planned primary completion date changed from 28 Oct 2022 to 3 Mar 2022.